Abstract:
Die Erfindung betrifft neue Behandlungsstrategien von Krebs, welche auf der Inhibierung der sauren Lipase basieren. Darüber hinaus betrifft die Erfindung Verfahren zum Auffinden neuer Wirkstoffe, welche zur Krebstherapie geeignet sind.
Abstract:
The present invention relates to the monitoring of disease progression and diagnosis of Insulin Resistance in diabetes by measuring levels of butyrylcholinesterase in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes.
Abstract:
The invention provides a simple colorimetric assay method for screening for propensity for, or occurrence of, neurodegeneration in the brain. The assay relies on measuring enzymatic activity of a soluble monomeric form of acetylcholinesterase (G 1 -AChE) added to biological samples such as serum or plasma samples. Exogenous G 1 -AChE with such samples from patients with, for example, Motor Neurone Disease associated with amyotrophic lateral sclerosis, Parkinson's disease or Alzheimer's disease has selectively been found to exhibit significantly higher activity than in similarly treated control samples.
Abstract:
Protein markers of toxicity and efficacy for drugs are determined. For example, methods and reagents are disclosed for determining whether a patient receiving an antilipemic drug, especially a statin or HMGCoA reductase inhibiting drug, is experiencing drug efficacy and/or toxicity. Individual susceptibility is also determined prior to treatment. Also, drug discovery of similar acting candidates and their likelihood of being toxic or effective is determined by analysis of all proteins in a sample simultaneously by 2-dimensional gel elecrotphoresis.
Abstract:
The present invention relates to a method for the detection of a marker protein (acetylcholinesterase or amyloid beta precursor protein) in a sample of saliva, that may be used as a diagnostic test for Alzheimer's disease or as marker of response to therapeutic intervention of a patient.
Abstract:
The invention relates to a method for the determination and measurement of deltamethrin. Said method comprises measuring deltamethrin concentration amperometrically with a biosensor comprising acetylcholinesterase immobilized on a magnetic bead as a biorecognition element.
Abstract:
본 발명은 배위적으로 불포화된 자리(coordinatively unsaturated site; CUS)에 아민이 도입된 철 함유 다공성 유무기 혼성체를 유효성분으로 포함하는 과산화물을 이용한 산화반응용 촉매, 상기 촉매를 포함하는 과산화수소, 콜린 및 아세틸콜린 검출용 조성물, 및 상기 조성물을 포함하는 뇌신경질환 진단용 조성물에 관한 것이다.
Abstract:
The present invention relates to a potency assay for skeletal muscle derived cells (SMDC), the potency assay comprises the steps of (a) measuring ACh E activity of SMDC, and (b) evaluating the potential of the SMDC to be used for the treatment of skeletal muscle dysfunction based on the AChE activity measured in step (a). Moreover, the present invention relates to skeletal muscle derived cells (SMDC) for use in the treatment of a muscle dysfunction. Finally, the present invention relates to the use of AChE activity as an in vitro differentiation marker for skeletal muscle derived cells and to a kit for performing the potency assay according to the present invention.
Abstract:
La presente invención se refiere a un método para determinar la enfermedad de Alzheimer mediante la detección de glicoproteínas portadoras del glicoepítopo HNK-1, a un método para determinar la progresión de la enfermedad de Alzheimer y al uso de un kit para llevar a cabo dichos métodos.